Mineralys Therapeutics, Inc. (MLYS) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call shows mixed signals: a decrease in net loss and strong intent from healthcare professionals to prescribe lorundrostat are positive, but increased expenses and management's avoidance of specifics during the Q&A raise concerns. The company's confidence in their product and ongoing trials suggests stability, while lack of detailed guidance and partnership updates tempers optimism. These factors balance each other out, leading to a neutral sentiment rating.
Key Financial Performance
Cash, Cash Equivalents, and Investments $593.6 million as of September 30, 2025, compared to $198.2 million as of December 31, 2024. The increase is attributed to funding activities sufficient to support operations into 2028.
R&D Expenses $31.5 million for Q3 2025, compared to $54 million for Q3 2024, a decrease of $26.8 million. The reduction is due to the conclusion of the lorundrostat pivotal program in Q2 2025, partially offset by increased compensation expenses and clinical supply manufacturing costs.
G&A Expenses $9.7 million for Q3 2025, compared to $6.1 million for Q3 2024, an increase of $3.6 million. The rise is due to higher compensation expenses, professional fees, and other administrative costs.
Total Other Income, Net $4.2 million for Q3 2025, compared to $3.8 million for Q3 2024, an increase of $0.4 million. This is primarily due to increased interest earned on investments in money market funds and U.S. treasuries.
Net Loss $36.9 million for Q3 2025, compared to $56.3 million for Q3 2024, a decrease of $19.4 million. The reduction is primarily due to lower R&D expenses.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Lorundrostat NDA Submission: The company is preparing to submit an NDA for lorundrostat, a treatment for uncontrolled or resistant hypertension, by late Q4 2025 or Q1 2026. The submission is supported by robust data from multiple clinical trials.
Clinical Trial Results: Lorundrostat demonstrated significant and sustained reductions in systolic blood pressure in the Launch-HTN and Advance-HTN trials. It showed efficacy across diverse patient populations, including those with resistant hypertension.
Explore-CKD Trial: Lorundrostat showed clinically meaningful reductions in systolic BP and urinary albumin creatinine ratio in patients with hypertension and chronic kidney disease. 77% of surveyed healthcare professionals indicated willingness to prescribe it.
Explore-OSA Trial: Enrollment completed for a trial evaluating lorundrostat in patients with obstructive sleep apnea and hypertension. Results expected in Q1 2026.
Market Access Planning: The company is prioritizing payer engagement and medical communications to ensure commercial readiness for lorundrostat.
Financial Position: The company ended Q3 2025 with $593.6 million in cash and investments, sufficient to fund operations into 2028.
R&D and G&A Expenses: R&D expenses decreased to $31.5 million in Q3 2025 due to the conclusion of pivotal trials, while G&A expenses increased to $9.7 million due to higher compensation and professional fees.
Focus on Hypertension and Comorbid Conditions: The company is extending lorundrostat's profile to treat hypertension with comorbid conditions like chronic kidney disease and obstructive sleep apnea.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Risks: The company is preparing an NDA submission for lorundrostat, which involves regulatory uncertainties. Any delays or issues in the approval process could adversely impact the company's timeline and commercialization plans.
Market Access and Payer Engagement: The company is prioritizing market access planning and payer engagement to ensure the value of lorundrostat is understood. Failure to secure favorable reimbursement terms or payer acceptance could limit the drug's market potential.
Clinical Trial Risks: Ongoing trials, such as the Phase II Explore-OSA trial, carry inherent risks. Unsuccessful trial outcomes could hinder the extension of lorundrostat's profile in treating hypertension with comorbid conditions.
Financial Risks: Despite a strong cash position, the company reported a net loss of $36.9 million for Q3 2025. Continued losses could strain financial resources if commercialization or additional funding efforts are delayed.
Competitive Pressures: The company operates in a competitive market for hypertension treatments. Failure to differentiate lorundrostat as a best-in-class therapy could impact its commercial success.
Operational Risks: Increased G&A expenses due to higher compensation, professional fees, and administrative costs could strain operational efficiency if not managed effectively.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
NDA Filing Timeline: The company plans to submit the NDA for lorundrostat either late in the fourth quarter of 2025 or in the first quarter of 2026.
Lorundrostat Commercialization: The company is advancing market access planning and payer engagement to ensure the value of lorundrostat is well understood. Efforts include expanding medical communications capabilities and preparing for a successful launch.
Explore-OSA Trial Results: Top-line results from the Phase II Explore-OSA trial, evaluating lorundrostat in patients with obstructive sleep apnea and hypertension, are expected in the first quarter of 2026.
Explore-CKD Trial Outcomes: Lorundrostat demonstrated clinically meaningful reductions in systolic blood pressure and urinary albumin creatinine ratio in patients with chronic kidney disease and hypertension. This supports its potential use in treating comorbid conditions.
Unmet Needs in Hypertension: The company emphasizes the significant unmet need in treating uncontrolled and resistant hypertension, affecting over 20 million people in the U.S., and highlights lorundrostat's potential as a best-in-class therapy.
Clinical Data Strength: The company is confident in lorundrostat's clinical data, which demonstrate meaningful blood pressure reduction, 24-hour control, and safety across diverse and difficult-to-treat patient populations.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What would the minus 9-millimeter mercury have been without adjustments for discontinuations in the resistant hypertension population?
A:The analysis without adjustments for discontinuations was not conducted as it was not part of the plan. The company emphasized the importance of accounting for all subjects enrolled, including discontinuations and patient outcomes. Estimations on imputation are complex and require raw data, but reductions could vary by 3 to 5 millimeters of mercury depending on the imputation method.
Q:Have you looked at day and night blood pressure differences for Advance-HTN, and was there any difference?
A:The company has measured blood pressure in the morning before the day's dose and is confident in the 24-hour control provided by lorundrostat. While nighttime data has not been published or disclosed, they are comfortable with the results from Target-HTN and Advance-HTN studies, which validate 24-hour control.
Q:Can missing data or invalid baseline measurements be excluded in the primary analysis based on FDA requirements?
A:The company stated that handling missing data must be pre-discussed with the FDA and included in the statistical analysis plan (SAP). Various methods, such as 'jump to reference,' are used, but these must be negotiated in advance. If not pre-specified before database lock, adjustments cannot be made later.
Q:Can you provide more color on the pre-NDA feedback and any final steps before filing?
A:The company did not disclose specific details but mentioned there were no surprises in the pre-NDA feedback. They are confident in their data set and are progressing well with long-term safety data. They aim to file by the end of the year or early next year.
Q:Can you provide updates on any partnering discussions?
A:The company continues to view partnering as a key component for ex-U.S. commercialization and maximizing value. They are confident in lorundrostat's best-in-class profile and are focused on maximizing its value for patients, physicians, and investors.
Q:What are your expectations for the open-label extension trial, and when can we expect an update on the data?
A:The open-label extension trial is progressing well with no surprises. The company is confident in the safety profile and plans to publish results after the last subject completes the trial.
Q:How do you expect to leverage data from the ongoing Explore-OSA trial?
A:The company aims to demonstrate lorundrostat's benefits beyond blood pressure reduction, addressing related comorbidities like CKD and OSA. This data will help inform prescribing decisions and enhance lorundrostat's profile.
Q:Do you see any major differences between lorundrostat and Bax, and what kind of partnerships are you looking for?
A:The company believes lorundrostat has a best-in-class profile and that aldosterone synthase inhibitors (ASIs) are a differentiated class addressing significant unmet needs. They are exploring partnerships for both commercial and developmental opportunities to maximize lorundrostat's value.
Q:Do you think AstraZeneca's small enrollment of African-American patients in Bax24 could have affected the results?
A:The company emphasized the importance of diverse representation in their trials, with over 50% African-American patients in Advance-HTN and nearly 30% in Launch-HTN. They found no racial differences in response to lorundrostat, highlighting its efficacy across populations.
Q:What percentage of patients achieved their blood pressure goals with lorundrostat in Advance and Launch?
A:In Launch-HTN, 44% of patients achieved their goal at week 6, and in Advance-HTN, 42% achieved their goal at week 4. The odds ratio of achieving the goal was over 3 in each study.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the pre-NDA feedback, stating only that there were no surprises. They also did not disclose nighttime blood pressure data from Advance-HTN, despite being asked about it. Additionally, they did not provide concrete updates on partnering discussions, only reiterating their general strategy.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ABPM treat
AHA guideline
ARB Phase
ASI space
ASN Kidney
African Americans
Americans participant
Explore CKD
Explore OSA
Mineralys
NDA submission
afternoon
aldosterone production
background medication
comorbid condition
condition blood
efficacy lorundrostat
feedback
group participant
hour ABPM
hypertension comorbid
lorundrostat class
lorundrostat profile
lorundrostat reduction
participant background
participant hypertension
participant lorundrostat
result trial
risk patient
safety efficacy
spectrum
subgroup
therapy
trial safety
MLYS Transcript
Mineralys Therapeutics, Inc. (MLYS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Neutral6-11
Mineralys Therapeutics, Inc. (MLYS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Neutral5-12
Mineralys Therapeutics, Inc. (MLYS) Q1 2026 Earnings Call Transcript
Unknown5-7
The earnings call summary shows positive financial performance with revenue and net income growth, but lacks discussion on strategic initiatives or operational updates. The Q&A section provided no additional insights or concerns. The absence of strategic updates or shareholder returns, combined with positive but not exceptional financials, suggests a neutral sentiment. Without market cap data, the stock's potential reaction is uncertain, but likely minimal.
Mineralys Therapeutics, Inc. (MLYS) Q4 2025 Earnings Call Transcript
Positive3-12
The company's strategic focus on NDA filing, market access, and commercialization planning for lorundrostat indicates a positive outlook. The Q&A reveals confidence in payer engagement and differentiation strategies, despite some uncertainties in commercial specifics. The positive clinical data and emphasis on significant unmet needs in hypertension further support a positive sentiment. However, the lack of specific details in some responses and the short duration of the Phase II OSA study may temper expectations slightly, but overall, the sentiment remains positive.
MLYS Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
